drugset
drugset / Trial / NCT05624606

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

NCT05624606 ↗

Phase 1/2 Completed 682 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza mRNA Vaccine MRT5410 compared to an active control (QIV SD, QIV HD \[adults ≥ 65 years of age only\], or RIV4) in adults 18 years of age and older.

Timeline

Start
2022-11-28
Primary completion
2024-03-28
Completion
2024-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject MRT5410 Messenger RNA (mRNA) — Intramuscular
Comparator QIV-HD Vaccine — Intramuscular
Comparator RIV4 Vaccine — Intramuscular
Comparator Standard Dose Quadrivalent Influenza Vaccine Vaccine — Intramuscular

Indications

No indication recorded.